The ATP-dependent 6-phosphofructokinase (EC 2.7.1.11, phosphofructokinase-1, ATP: Dfructose-6-phosphate-1-phosphotransferase; Pfk) catalyzes the phosphorylation of fructose 6-phosphate (Fru-6-P) to fructose 1,6-bisphosphate (Fru-1,6-P 2 ). This irreversible reaction is considered to be one of the rate-limiting steps of glycolysis (1) (2) (3) . In eukaryotes the Pfk activity is modulated by a number of allosteric regulators, e.g. ATP, AMP, NH 4 + , fructose 2,6-bisphosphate (Fru-2,6-P 2 ), citrate and acyl-CoA (4). Most eukaryotic Pfk are homo-and heterooligomeric enzymes consisting of subunits which evolved from a single ancestor prokaryotic Pfk through gene duplication and mutational events (5, 6) .
In eukaryotes the N-terminal half of a Pfk subunit mediates the catalytic function, whereas in the C-terminal half allosteric ligand binding sites have evolved from former catalytic and regulatory sites (5, 7, 8) . It is assumed that specific amino acid residues involved in 2 catalytic and regulatory functions of Pfk from E. coli (9, 10) are conserved in yeast and mammalian Pfk genes. For example, citrate inhibits the enzyme through interaction with sites that have evolved from a duplicated allosteric site (PEP binding site) (11, 12) whereas sites for activators, e.g. Fru-2,6-P 2 , have evolved from the catalytic site (Fru-6-P) of the ancestral precursor (13, 14) . In contrast, the ATP substrate binding site from the ancestral prokaryotic Pfk did not evolve to a new inhibitory ATP binding pocket (13, 15) and it remains unclear as to how adenine nucleotides implement their allosteric inhibitory (ATP) and activating (AMP) effects. Note that ATP serves as a substrate and as an allosteric inhibitor of eukaryotic Pfk. ADP can act as an activator at µM concentrations but inhibits eukaryotic Pfk activity at mM concentrations (16) .
Until recently, no high resolution structure of eukaryotic Pfk was available to prove the conservation and the functional relevance of allosteric ligand binding sites.
In 2011, crystal structures of three eukaryotic Pfk from the yeasts Pichia pastoris (15) and S. cerevisiae (13) and from rabbit muscle (13) were determined. In the crystal structure of P. pastoris Pfk an additional ATP binding pocket was found in each β chain which was presumed to be an inactivating site (15) . In the structure of rabbit muscle Pfk this ATP binding site was also discovered in the N-terminal domain of each subunit with either ADP or ATP bound to it. An additional novel ADP binding site was found in the center of each subunit (13) . This was proposed as an activating (ADP binding) site because replacement by ATP failed (Fig. 1) . Neither of these two binding sites evolved from a regulatory or catalytic binding site in bacterial Pfk. Fig. 1B shows a superposition of the E. coli Pfk with its two equivalent effector binding sites at the subunit interfaces. The superposition of rabbit and E. coli Pfk suggests that the effector binding sites of the bacterial protein are maintained in the mammalian enzyme but only a phosphate ion is bound to this site. Since ADP is found in at least two binding sites the functional relevance of the individual binding sites is still unclear. Furthermore, it is unknown whether additional binding sites exist in Pfk mediating the activating and inhibitory effects of adenine nucleotides. There is no crystal structure with AMP bound to Pfk available yet.
Here, we experimentally addressed the functional relevance of the canonic activating and inhibitory adenine nucleotide binding sites through mutagenesis and kinetic studies. We functionally qualified the adenine nucleotide binding sites and identified a reciprocal linkage between these allosteric binding sites.
EXPERIMENTAL PROCEDURES Materials
If not otherwise stated, all chemicals and standard substances were purchased from Sigma Aldrich (Taufkirchen, Germany), C. Roth GmbH (Karlsruhe, Germany), Roche Applied Science (Mannheim, Germany), Fermentas GmbH (St. Leon-Rot, Germany) and BD (New Jersey, USA). Restriction enzymes and primers were purchased from New England Biolabs (Frankfurt/Main, Germany) and Invitrogen (Karlsruhe, Germany), respectively.
Methods
Strains and growth conditions -The E. coli strain DH5α was used for the cloning experiments. Transformants were selected on LB medium containing 100 µg/ml ampicillin. 246 and Lys 386 were selected based on the crystal structure of rabbit skeletal muscle Pfk (PDB: 3O8N, 3O8L). These residues participate in the proposed ADP activator and the ATP inhibitor binding sites (13, 15) and are conserved between the human and rabbit muscle Pfk.
Construction of mutant Pfk -All mutants were constructed using PCR-based site-directed mutagenesis and the fragments were cloned into the plasmid pJJH71PFK (kindly provided by Prof. Dr. Jürgen J. Heinisch, University of Osnabrück (18)). The resulting plasmids were sequenced to ensure sequence correctness.
Expression and purification of recombinant enzymes -Transformation of yeast strain HD114-8D was performed with LiAc/ssDNA/PEG (19) . Transformants were grown in liquid medium with shaking at 30 °C. After 24 h the cells were harvested by centrifugation at 5700 x g for 15 min at 4 °C and washed twice with water and once with a 50 mM potassium phosphate buffer, pH 7.2, containing 1 mM EDTA, 5 mM ME and 0.5 mM PMSF (buffer A). Cell disruption was performed according to (20) in buffer A with 50 mM NaF, 50 µM Fru-1,6-P 2 and protease inhibitor cocktail (Roche Applied Science). Following steps were carried out at 4° C unless described otherwise. The mixture was centrifuged at 75 000 x g for 30 min. The supernatant was subjected to protamine sulphate precipitation (0.2 % w/v) (21) with stirring for 5 min. After centrifugation the pellet was discarded and the supernatant was precipitated with PEG 6000 (5 % w/v) for 30 min with stirring. After centrifugation as before, the pellet was dissolved in buffer B (50 mM Tris/HCl, pH 8.0, 50 µM Fru-1,6-P 2 , 0.1 mM EDTA, 5 mM ME, 50 mM NaF, 0.5 mM PMSF; according to (21) ). Cibacron Blue F3GA-Sephadex™ G75 (prepared according to (22) (600 x 21.2 mm; Phenomenex, Aschaffenburg, Germany). The column was equilibrated with buffer A containing 50 µM Fru-1,6-P 2 , pH 7.5. Fractions with Pfk activity were pooled, 2 mM ATP added and the enzyme solution was concentrated as before. The purified enzyme can be stored with 30 % glycerol (v/v) at -20 °C for two weeks without loss of activity. For kinetic studies of wild type and mutant Pfk the partially purified enzyme after affinity chromatography with F3GA-Sephadex™ was used.
Pfk activity assay -During preparation, Pfk activity was measured spectrophotometrically at 340 nm and 25 °C according to (20) except pH was 8.5 and 1.2 mM ATP was used. The reaction was started with the addition of a 2-5 µl enzyme sample. Kinetic studies were performed in 50 mM HEPES, 100 mM KCl, 5 mM MgCl 2 , pH 7.0, 0.2 mM NADH, 0.45 U/ml aldolase, 4.5 U/ml triosephophate isomerase and 1.5 U/ml glycerole phosphate dehydrogenase. ATP, Fru-6-P, AMP and ADP were used as indicated. In the case of the ATP-inhibition experiments the MgCl 2 concentration was 15 mM. Auxiliary enzymes were dialysed before use (Micro Bio-Spin 6, Bio-Rad Laboratories, Munich, Germany). The reaction was started by the addition of 5 µl enzyme sample appropriately diluted with 50 mM sodium phosphate buffer, pH 7.2, containing 10 % glycerol. Curve fittings for kinetic parameters were generated by either Michaelis-Menten or Hill equations using Prism (GraphPad Software, Inc.La Jolla). Thus, the hyperbolic and the sigmoid parts of the curves (V min to V max ) were fit to Michaelis-Menten and Hill equations, respectively. To exclude artifacts in the determination of the kinetic parameters using partially purified enzymes, wild type and two mutants (N 341 A, R
246
A/K 386 A) were purified to homogeneity. Since there were no differences in the kinetic parameters, all mutant Pfk were partially purified (see above) and tested in kinetic assays.
RESULTS

Identification of the activating site
In the crystal structure of rabbit skeletal muscle Pfk, the diphosphate moiety of ADP in the allosteric activation site is mainly coordinated by Ser 377 and Lys 678 (Fig. 1C) . Mutation of the latter two residues to Ala significantly increased K 0.5 for ADP (Table 1 ). The K 0.5 for ADP of the double mutant S 377 A/K 678 A was further increased (see Table 1 ) indicating that this ADP binding site is indeed the allosteric activating site in Pfk. The AMP activation of S 377 A and K 678 A was less pronounced (see Table 1 ) probably because of weaker or absent interaction between these residues and the monophosphate moiety of AMP. Next, we mutated Asn 341 to Ala, which interacts with the ribose of ADP (Fig. 1C) and probably also AMP. In contrast to S 377 A and K 678 A, N 341 A not only showed increased K 0.5 values for ADP but also significantly reduced enzyme activation by AMP ( Fig. 2A/B A had no significant effects on Pfk activity compared to the wild-type enzyme (data not shown) most probably because of the very conservative structural change. In contrast, mutation of the other three residues to Ala significantly increased K i for ATP and ADP (Fig. 4, Table 3 ). K i values for ATP and ADP of the double mutant R 246 A/K 386 A were further increased (Fig. 4, Table 3 ), indicating that this nucleotide binding site is indeed the allosteric inhibition site of ADP and ATP in mammalian Pfk. Interestingly, all mutants showed significantly higher basal activity in the absence of the activators AMP and ADP (Fig. 4B , Table 3 ), suggesting that the enzyme is constitutively activated due to mutation in the allosteric inhibitor site. The Fru-6-P dependency of the Fig. 4 ).
DISCUSSION
Pfk activity underlay strong allosteric regulation by several effectors including adenine nucleotides. Crystal structures of prokaryotic and eukaryotic Pfk revealed a number of adenine nucleotide molecules bound in the catalytic center as well as in allosteric binding sites (Fig. 1A/B) . In the crystal structure of rabbit skeletal muscle Pfk (13) ADP was found in two binding sites (Fig. 1C/D) which were different to the well characterized allosteric binding sites in prokaryotic Pfk (Fig. 1B) . Because ADP can activate (at µM concentration) and also inactivate (at mM concentration) the enzyme, we approached the functional relevance of these two nucleotide binding sites by site-directed mutagenesis. In one crystal structure of the rabbit skeletal muscle, Pfk ATP was found in one of the two ADP binding sites (Fig. 1E) suggesting this as the inhibitory allosteric site, however an experimental proof was missing. (Fig. 1C) , binding of the monophosphate residue of AMP may involve additional or other residues. Only a crystal structure of muscle Pfk with AMP bound may clarify detailed coordination of this nucleotide in the activating allosteric site. Mutation of Asn 341 was more efficient in increasing the K 0.5 values of both ADP and AMP (Table 1) . Since the backbone nitrogen atom of N 341 interacts with the ribose of ADP, the side chain is probably involved in the transmission of the allosteric signal or necessary for the correct positioning of the backbone chain. Most strikingly however, K i values of ADP and ATP were significantly shifted towards lower concentrations suggesting an increase of the effector affinity at the allosteric inhibitory binding site or an enhanced transduction of the inhibitory effect of ATP and ADP ( Fig. 2A/C (Table 3) , strongly supporting the postulated function as the inhibitory allosteric site. However, Pfk activity was almost at the maximum in the absence of the activator AMP or ADP (Fig. 4B) indicating constitutively activated mutant enzymes. The maximum activity of e.g. R 246 A/K 386 A was not significantly different from the wild type and the specific activity of highly purified Ala mutants did not differ from the wild type enzyme under optimal conditions excluding gross structural changes in the mutants. It appears that mutations of the inhibitory allosteric site "locked" the enzyme in an active conformation mimicking the state in the presence of AMP. This is supported by the fact that Fru-6-P dependency of the Fig 4A/B ). This indicates a more complex interplay of the allosteric sites or several (dissociable) active states. From recent studies we know that the smallest active enzyme form of mammalian Pfk consists of four subunits but higher oligomeric complexes exists, which are also functional (23, 24) . Physiologically, AMP and µM concentration of ADP promote enzyme activation and mM concentrations of ADP and ATP promote enzyme inhibition. This allosteric regulation directly couples cellular energy metabolism to cellular ATP/AMP ratio. Our data now suggests that this ATP/AMP-driven allostery is further fine-tuned by a reciprocal linkage of the two functionally opposed allosteric sites. Mutation of the activating allosteric site reduces the activating effect of AMP and ADP and synergistically increases the inhibitory effect of ATP and ADP. Vice versa, mutation of the inhibitory allosteric site increases K i values of ATP and ADP and results in a constitutively activated enzyme. One may speculate that mutation or ligand occupation of one allosteric site lead to structural changes followed by changes in the affinity of the opposite allosteric site. For example, occupation of the allosteric activator site by AMP in the wild type Pfk decreases the affinity of ATP at the allosteric inhibitory site. Indeed, early studies with the skeletal muscle Pfk showed that the binding of AMP resulted in an antagonism of ATP inhibition by decreasing the affinity of ATP binding (25) . Further evidence for such mechanistic explanation comes from the crystal structures of the prokaryotic Pfk from E. coli. In the inactive state, the AMP binding site is structurally different compared to the active state (10) . Crystal structure of eukaryotic Pfk clearly showed that the allosteric nucleotide binding sites are different from those in the prokaryotic Pfk (13, 15) . Therefore, reciprocal linkage of functionally opposed allosteric binding sites must have developed independently in prokaryotic and eukaryotic Pfk giving an impressive example of convergent evolution at the molecular level. Although a reciprocal linkage of functionally opposite allosteric binding sites is in agreement with the extended Monod-Wyman-Changeux model of allostery (26) this allostery model has been shown inappropriate in a certain number of cases. For prokaryotic Pfk, the classical twostate model is not sufficient to describe the allosteric behavior (27) so additional models of allostery were developed (26) (27) (28) (29) . Since mammalian Pfk are even more complex (in terms of structure and regulation) than prokaryotic Pfk, appropriate crystal structures of the various states are required to clarify whether the functionally opposed allosteric sites are linked within a subunit or between subunits. In sum, we assigned two new allosteric adenine nucleotide binding sites to be the activating and inhibitory nucleotide binding sites. The latter is occupied by ATP or ADP. The novel ADP binding site found in the crystal structure of mammalian Pfk is the activating allosteric site and binds also AMP. Our data strongly supports that activating and inhibitory allosteric binding sites do not only regulate the catalytic Pfk activity but also modulate the properties of each other in a reciprocal manner. This crosstalk between the allosteric nucleotide binding sites may further fine-tune Pfk activity depending on the ATP/AMP ratio. 341 A was determined with 0.5 mM Fru-6-P and 1 mM ATP. Activity is expressed relative to maximal activity (V) for each enzyme under these conditions (V values of wild type were 295 U/ml and 233 U/ml for AMP and ADP, respectively and 147 U/ml and 57 U/ml for N 341 A). (C) For ATP, assays were performed at 2 mM Fru-6-P. Activity is expressed as a relation between the measured (v) and maximal possible (V) activity for each enzyme under these conditions (V values of wild type were 396 U/ml and 434 U/ml without effectors and 1 mM AMP, respectively and 147 U/ml and 247 U/ml for N 341 A). Dotted line without effectors; continuous line with 1 mM AMP. Data are means ± SEM of three independent experiments each performed in duplicate. Table 1 . For ADP, kinetic properties were determined with 0.5 mM Fru-6-P and 1 mM ATP. Residual Pfk activity was defined as percentage of enzyme activity at 4.5 mM ADP and maximal activity of each enzyme under these conditions. The values are means ± SEM of three independent experiments. nd: not detectable.
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